Opioid Use Disorder for Hospitalists in the Fentanyl Era

---

ONLINEAAPACMECNEOpioidDEA-Required Opioid TrainingComplimentary - No FeeState Required CME

Tuesday, August 16, 2022, 8:41 AM - Saturday, August 16, 2025, 9:41 AM

The re-emergence of fentanyl has created a heightened need for clinicians to employ medications designed to treat opioid use disorder (MOUD) and implement harm reduction strategies. 

1. Review epidemiology of opioid use disorder including the re-emergence of fentanyl
2. Practice evidence-based medicine for patients with OUD by using medications for opioid use (MOUD) disorder and harm reduction strategies
3. Analyze the benefits of short-acting opioids as a tool for withdrawal and pain in patients with active OUD

In support of improving patient care, Penn Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

Physicians: Penn Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses: The activity awards 1.0 NCPD hours

Pharmacists: This knowledge-based activity is approved for 1.0 ACPE contact hours of continuing pharmacy education credit. UAN JA0000324-0000-22-035-H04-P

Opioid Education: This activity is approved for 1.0 hours in Opioid Education. 

AMA PRA Category 1 Credits™ (1.00 hours), Non-Physician Attendance / Participation (1.00 hours), NCPD Hours (ANCC) (1.00 hours), Opioid Education (1.00 hours), American Academy of Physician Assistants (1.00 hours)

Mitigation of Relevant Financial Relationships

Penn Medicine adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity.